Diary - News
All news First Patient Randomized in Multiple Dose Cohort Of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced that the first patient has been included in the multiple dose cohort of the Phase1/1b trial with TG1050, Transgene’s immunotherapy product candidate for the treatment of chronic hepatitis B virus (HBV) infection (NCT: 02428400).
